Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
35,548 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Comparison Between EGFR-TKI Efficacy in Early-Stage Non-small Cell Lung Cancer and Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis.
Wang B, Yao Y, Chen Z, Wu R, Sun J, Li X, Xu X, Si Y, Liu H. · Lung · 2026 · cited 0 timesmeta-analysis, comparative study
- Oncologic efficacy and safety of stereotactic body radiotherapy for oligometastatic non-small cell lung cancer: a systemic meta-analysis.
Jeong JU, Yoo GS, Lee JH, Chan Ahn Y, Rim CH, Chie EK, Chang AR, Korean Cancer Association Oligometastasis Working Group. · Clin Exp Metastasis · 2026 · cited 0 timesmeta-analysis, systematic review
- Biomarkers of nivolumab benefit in resectable non-small cell lung cancer.
Cascone T, Awad MM, Spicer JD, He J, Lu S, Tanaka F, Cornelissen R, Petruzelka LB, Gao Y, Pujol JL, Ito H, de Oliveira Muniz Koch L, Ciuleanu TE, Wu L, Bohnet S, Watanabe Y, Taube JM, Deutsch JS, Erdmann CC, Meadows-Shropshire S, Neely J, Ip V, Hung YH, Sathyanarayana P, Bhatia S, Chu K, Blum SI, Lucherini S, Eddy N, Yadav A, Provencio M. · Nature · 2026 · cited 1 timesOpen accessrandomized controlled trial
- Comparative effectiveness and safety of almonertinib in EGFR-mutated non-small cell lung cancer: an integrated evidence synthesis
Rong B, Pan H, Fu T, Liu Y, Yang P, Zhang J, Wang Y. · Front Pharmacol · cited 0 timesOpen accesssystematic-review, review
- Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Chaft JE, Sun Z, Rudin CM, Khullar OV, Simone CB, Oettel K, Kozono D, Sunkara R, Faller B, Isbell JM, Hugec V, Shipstone A, McGary EC, Clarke JM, Talsania A, Ding L, Govindan R, Sands JM, Heymach JV, Raez LE, Malik SM, Stinchcombe TE, Mandrekar SJ, Bradley J, Gerber DE, Vokes E, Gandara D, Staley C, Ramalingam SS. · JAMA · 2026 · cited 11 timesclinical trial, phase iii, comparative study
- Rilvegostomig for Metastatic Non-Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.
Rohrberg KS, Brandão M, Castañón Álvarez E, Felip E, Gort E, Hiltermann TJN, Izumi H, Kim DW, Kim SW, Paz-Ares L, Solomon B, Smit EF, Wauters E, Yoshida T, Ayyoub A, Chen HA, Colebrook S, Hamidi NN, Kuziora M, Lim K, Achour I, Drachsler MW, Karanovic D, Liu N, Cho BC. · Clin Cancer Res · 2026 · cited 1 timesOpen accessclinical trial, phase ii, multicenter study
- Sex difference in survival benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer: A meta-analysis.
Liu T, Song D, Chen J, Yao J, Liao J, Dang J. · PLoS One · 2026 · cited 0 timesOpen accessmeta-analysis
- Local ablative treatment for oligoprogression during immunotherapy in metastatic non-small-cell lung cancer: a systematic review and meta-analysis.
Massalha I, Hijab A, Zabit R, Zidan J, Wiesel O, Peled N. · Oncoimmunology · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Comparative effectiveness and safety of almonertinib in EGFR-mutated non-small cell lung cancer: an integrated evidence synthesis.
Rong B, Pan H, Fu T, Liu Y, Yang P, Zhang J, Wang Y. · Front Pharmacol · 2026 · cited 0 timessystematic review
- Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and αC-helix compressing mutations.
Le X, Wang J, Yu Y, Zhao Y, Planchard D, Gao B, Spira A, Liu J, Li X, Gadgeel S, Leighl N, Zhang J, Hayashi H, Nishio M, Mazieres J, de Langen AJ, Pérol M, Yoh K, Forster MD, Goto Y, de Miguel Luken M, Franco Perez FF, Chu Q, Parakh S, Nilsson MB, Jiang Y, Hu T, Wang C, Baio N, Musib L, Mounir Z, Kowanetz M, Wang S, Yea S, Hsu J, Lutzker S, Heymach JV, Juan-Vidal O, Riess JW. · Cancer Cell · 2026 · cited 1 timesclinical trial, phase i, randomized controlled trial
- Advances in Aptamer Diagnostics Targeting Non-Small-Cell Lung Cancer: A Systematic Review.
Agnello L, Leone I, Affinito A, Esposito CL, Catuogno S, D'Agostino A, Salvatore M, Condorelli G, Nuzzo S. · Int J Mol Sci · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Discordance of PD-L1 expression between primary and paired metastatic non-small cell lung cancer: a systematic review and meta-analysis.
Zhang L, Gao Y, Wang X, Gu Y, Hou L, Wang X. · Front Immunol · 2026 · cited 0 timesOpen accessmeta-analysis, research support, non-u.s. gov't
- Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial.
Yue D, Cappuzzo F, Wang W, Liu H, Chen Q, Wang S, Leaw SJ, Yao B, Barnes FB, Barnes G, Wang C. · Future Oncol · 2026 · cited 0 timesOpen accessclinical trial, phase iii, multicenter study
- A Systematic Review and Meta-analysis of Clinical Trials in ALK-positive Non-small Cell Lung Cancer.
Basmajian K, Stepanyan Z, Sarkissian S. · Anticancer Res · 2026 · cited 0 timesmeta-analysis, systematic review
- Clinical outcomes of targeted treatment strategies for primary non-small cell lung cancer with MET alterations: a systematic review and meta-analysis.
Meng Z, Deng H, Han J, Ruan W, Xiao Y, Huang H, Wang J, Huang J. · Front Oncol · 2026 · cited 0 timessystematic review
- Stage II Non-Small Cell Lung Cancer: Upfront Surgery or Neoadjuvant Chemoimmunotherapy.
Tajè R, Gallina FT, Spicer JD. · Ann Thorac Surg · 2026 · cited 1 timesmeta-analysis, review
- The clinical trial landscape of bispecific antibodies in non-small cell lung cancer: mechanistic trends and developmental strategies.
Li Z, Wang X, Shi Q, Guo Y, Dong G, Liu Z. · Front Pharmacol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Divergent Tumor Immune Microenvironment and Response to Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer: A Single-Arm Phase II Trial.
Chen M, Li R, Cheng Z, Wei Y, Liu H, Zhou X, Zhao J, Zhang L, Zhong W, Huang B, Yu G, Li J, Xu Y, Wang M. · Clin Cancer Res · 2026 · cited 0 timesOpen accessclinical trial, phase ii
- Economic evaluations of next-generation sequencing for targeted therapy in non-small cell lung cancer: a systematic review.
Dai Z, Ye W, Zhou J, Tian L. · Front Public Health · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Lazertinib plus pemetrexed and carboplatin in patients with EGFR-mutant advanced non-small cell lung cancer after progression on lazertinib.
Hong MH, Shim BY, Kim CG, Kim YS, Lee S, Lee Y, Ahn BC, Ahn MJ, Ahn JS, Park S, Yeo JH, Hong SH, Jang IH, Lee KH, Kim HR. · Eur J Cancer · 2026 · cited 0 timesclinical trial, phase ii, multicenter study
- Radiomics-Based AI for Predicting Neoadjuvant Immunochemotherapy Pathological Response in Non-Small Cell Lung Cancer: Systematic Review and Meta-Analysis.
Jiang Z, Xu Y, Jia S, Liu H. · J Med Internet Res · 2026 · cited 2 timesOpen accessmeta-analysis, systematic review
- Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.
Zhou T, Zhou H, Gao F, Feng W, Jiang W, Huang L, Zhao F, Chen L, Ji M, Zhu J, Fang Y, Chen P, Wang P, Wu J, Zhuang L, Liu X, Deng M, Weng G, Li J, Yang C, Zhao H, Yang Y, Zhang L. · JAMA · 2026 · cited 1 timesclinical trial, phase iii, comparative study
- Systemic and intracranial activity of antibody-drug conjugates in patients with non-small cell lung cancer and brain metastases: A systematic review and meta-analysis.
Zhou S, Tan J, Patel V, Kishi N, Akhtar K, Benjamin S, Homsi J, Tsao CK. · Lung Cancer · 2026 · cited 1 timesmeta-analysis, research support, non-u.s. gov't
- A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial.
Oh MS, Lisberg AE, Dumitras C, Tran LM, Salehi-Rad R, Krysan K, Lim RJ, Shabihkhani M, Romero T, Li S, Zeng W, Jing Z, Li R, Kahangi BP, Tsvetkova O, Suh RD, Abtin F, Genshaft SJ, Oh SS, Fishbein GA, Greenwald DR, Kahlon KS, Anand SR, Ashouri S, Goldman JW, Lee JM, Zhou XJ, Elashoff DA, Garon EB, Liu B, Dubinett SM. · Nat Commun · 2026 · cited 0 timesOpen accessclinical trial, phase i, research support, u.s. gov't, non-p.h.s.
- Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.
Borghaei H, Balli D, Paz-Ares LG, Reck M, Lu S, Ramalingam SS, Brahmer JR, John T, Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Zurawski B, Pluzanski A, Lee JS, Agrawal S, Spires T, Neely J, Ip V, Eccles LJ, Chang H, Szustakowski JD, Bhatia S, Yadav A, Eddy N, Geese WJ, O'Byrne KJ. · Clin Cancer Res · 2026 · cited 0 timesOpen accessclinical trial, phase iii, randomized controlled trial
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.